Movatterモバイル変換

[0]ホーム
URL:

Skip to main content
Springer Nature Link
Log in

Vortioxetine: First Global Approval

  • R&D Insight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Vortioxetine is an orally administered small molecule developed by Lundbeck A/S for the once-daily treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD). Vortioxetine received its first global approval for MDD in the USA in September 2013 and regulatory approval for its use in this indication in the EU (where it has received a positive opinion) and Canada is awaited. The drug is a bis-aryl-sulphanyl amine compound that combines serotonin (5-HT) reuptake inhibition with other characteristics, including receptor activity modulation. In vitro studies indicate that vortioxetine is an inhibitor of the 5-HT transporter and is a 5-HT1D, 5-HT3 and 5-HT7 receptor antagonist, a 5-HT1A receptor agonist and a 5-HT1B receptor partial agonist. Animal and in vitro studies indicate that several neurotransmitter systems may be impacted by vortioxetine, with the drug enhancing levels of 5-HT, noradrenaline, dopamine, acetylcholine and histamine in certain areas of the brain, as well as modulating γ-aminobutyric acid and glutamate neurotransmission. Phase III trials of vortioxetine in both MDD and GAD have been conducted worldwide. This article summarizes the milestones in the development of vortioxetine leading to this first approval for MDD.

This is a preview of subscription content,log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
¥17,985 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Japan)

Instant access to the full article PDF.

Similar content being viewed by others

Explore related subjects

Discover the latest articles, news and stories from top researchers in related subjects.

References

  1. Kennedy SH. A review of antidepressant therapy in primary care: current practices and future directions. Prim Care Companion CNS Disord. 2013;15(2).

  2. Richelson E. Multi-modality: a new approach for the treatment of major depressive disorder. Int J Neuropsychopharmacol. 2013;16(6):1433–42.

    Article CAS PubMed Central  Google Scholar 

  3. H. Lundbeck AS and Takeda Pharmaceutical Company Limited. Takeda and Lundbeck announce FDA approval of Brintellix™ (vortioxetine) for treatment of adults with major depressive disorder [media release]. 01 Oct 2013.http://www.lundbeck.com.

  4. Food and Drug Administration. NDA approval [letter]. 2013.http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/204447Orig1s000ltr.pdf. Accessed 20 Nov 2013.

  5. H. Lundbeck A/S and Takeda Pharmaceutical Co Ltd. Brintellix (vortioxetine) tablets, for oral use: US prescribing information; 2013.http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204447s000lbl.pdf. Accessed 25 Oct 2013.

  6. Lundbeck AS. FDA accepts Takeda and Lundbeck’s filing for review of Brintellix (vortioxetine) for the treatment of major depression [media release]. 12 Dec 2012.http://www.lundbeck.com.

  7. H. Lundbeck AS and Takeda Pharmaceutical Company Limited. Takeda and Lundbeck announce the submission of a New Drug Application for vortioxetine, an investigational drug for the treatment of major depression, in the US [media release]. 2 Oct 2012.http://www.lundbeck.com.

  8. Lundbeck. Lundbeck files for regulatory approval of the novel multimodal antidepressant, vortioxetine, in Europe [media release]. 20 Sep 2012.http://www.lundbeck.com.

  9. European Medicines Agency. Summary of opinion (initial authorisation): Brintellix, vortioxetine; 2013.http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002717/WC500153088.pdf. Accessed 31 Oct 2013.

  10. H. Lundbeck AS. Third quarter report 2012: vortioxetine filed in the US and EU revenue from new products doubled [media release]. 6 Nov 2012.http://www.lundbeck.com.

  11. Bang-Andersen B, Ruhland T, Jorgensen M, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011;54(9):3206–21.

    Article CAS PubMed  Google Scholar 

  12. Areberg J, Luntang-Jensen M, Sogaard B, et al. Occupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjects. Basic Clin Pharmacol Toxicol. 2012;110(4):401–4.

    Article CAS PubMed  Google Scholar 

  13. Stenkrona P, Halldin C, Lundberg J. 5-HTT and 5-HT1A receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects. Eur Neuropsychopharmacol. 2013;23(10):1190–8.

    Article CAS PubMed  Google Scholar 

  14. Pehrson AL, Cremers T, Betry C, et al. Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters—a rat microdialysis and electrophysiology study. Eur Neuropsychopharmacol. 2013;23(2):133–45.

    Article CAS PubMed  Google Scholar 

  15. Mork A, Pehrson A, Brennum LT, et al. Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. J Pharmacol Exp Ther. 2012;340(3):666–75.

    Article CAS PubMed  Google Scholar 

  16. Mork A, Brennum LT, Fallon S, et al. Pharmacological profile of Lu AA21004, a novel multi-target drug for the treatment of mood disorders [abstract no. P.2.d.017]. Eur Neuropsychopharmacol. 2009;19:S439.

    Article  Google Scholar 

  17. Mork A, Montezinho LP, Miller S, et al. Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. Pharmacol Biochem Behav. 2013;105:41–50.

    Article PubMed  Google Scholar 

  18. Sanchez C, Pehrson AL, Betry C, et al. Vortioxetine (LU aa21004), an investigational multimodal antidepressant: differentiation from currently used antidepressants in preclinical rodent models [abstract]. Biol Psychiatry. 2013;73(9 Suppl 1):106S–7S.

    Google Scholar 

  19. Betry C, Pehrson AL, Etievant A, et al. The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT(3) receptor antagonism. Int J Neuropsychopharmacol. 2013;16(5):1115–27.

    Article CAS PubMed  Google Scholar 

  20. Riga MS, Celada P, Sanchez C, et al. Role of 5-HT3 receptors in the mechanism of action of the investigational antidepressant vortioxetine [abstract no. P.2.e.003]. Eur Neuropsychopharmacol. 2013;23 Suppl 2:S393–4.

    Article  Google Scholar 

  21. Dale E, Zhang H, Leiser SC, et al. Vortioxetine (Lu AA21004) disinhibits pyramidal cell output and enhances theta rhythms and long-term plasticity in the hippocampus [abstract no. P.2.e.004]. Eur Neuropsychopharmacol. 2013;23 Suppl 2:S394.

    Article  Google Scholar 

  22. Pehrson A, Li Y, Haddjeri N, et al. Vortioxetine, a novel multimodal antidepressant, modulates GABA and glutamate neurotransmission via serotonergic mechanisms [abstract no. P.1.g.014]. Eur Neuropsychopharmacol. 2013;23 Suppl 2:S196–7.

    Article  Google Scholar 

  23. Du Jardin KG, Liebenberg N, Muller H, et al. Single dose vortioxetine or ketamine but not fluoxetine increases expression of neuroplasticity related genes in the rat prefrontal cortex [abstract no. P.2.e.001]. Eur Neuropsychopharmacol. 2013;23 Suppl 2:S392.

    Article  Google Scholar 

  24. Guilloux J-P, Mendez-David I, Pehrson A, et al. Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. Neuropharmacology. 2013;73:147–59.

    Article CAS PubMed  Google Scholar 

  25. Li Y, Raaby KF, Sanchez C, et al. Serotonergic receptor mechanisms underlying antidepressant-like action in the progesterone withdrawal model of hormonally induced depression in rats. Behav Brain Res. 2013;256:520–8.

    Article CAS PubMed  Google Scholar 

  26. Haddjeri N, Etievant A, Pehrson A, et al. Effects of the multimodal antidepressant Lu AA21004 on rat synaptic and cellular hippocampal plasticity and memory recognition [abstract no. P.2.h.002]. Eur Neuropsychopharmacol. 2012;22 Suppl 2:S303.

    Article  Google Scholar 

  27. Leiser SC, Pehrson AL, Robichaud PJ, et al. Preclinical studies of the multimodal antidepressant vortioxetine support a potential for improvement of cognitive functions [abstract]. Neuropsychopharmacology. 2012;38:S164–5.

    Google Scholar 

  28. du Jardin KG, Jensen JB, Sanchez C, et al. Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism. Eur Neuropsychopharmacol. 2013. doi:10.1016/j.euroneuro.2013.07.001.

    Google Scholar 

  29. Theunissen EL, Street D, Hojer AM, et al. A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition. Clin Pharmacol Ther. 2013;93(6):493–501.

    Article CAS PubMed  Google Scholar 

  30. Wang Y, Nomikos GG, Karim A, et al. Effect of vortioxetine on cardiac repolarization in healthy adult male subjects: results of a thorough QT/QTc study. Clin Pharmacol Drug Dev. 2013;2(4):298–309.

    Google Scholar 

  31. Hojer AM, Sog B, Areberg J. Investigation of the absorption profile of Lu AA21004 [abstract no. P27]. Int J Psychiatry Clin Pract. 2011;15:25.

    Google Scholar 

  32. Mayer M, Xie J, Serenko M. Effect of formulation and food on the pharmacokinetics of Lu AA21004 in healthy subjects [abstract no. PII-49]. Clin Pharmacol Ther. 2012;91 Suppl 1:S69–70.

    Google Scholar 

  33. Areberg J, Sogaard B, Hojer A-M. The clinical pharmacokinetics of Lu AA21004 and its major metabolite in healthy young volunteers. Basic Clin Pharmacol Toxicol. 2012;111(3):198–205.

    CAS PubMed  Google Scholar 

  34. Uldam HK, Juhl M, Pedersen H, et al. Biosynthesis and identification of an N-oxide/N-glucuronide metabolite and first synthesis of an N-O-glucuronide metabolite of Lu AA21004. Drug Metab Dispos. 2011;39(12):2264–74.

    Article CAS PubMed  Google Scholar 

  35. Hvenegaard MG, Bang-Andersen B, Pedersen H, et al. Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012;40(7):1357–65.

    Article CAS PubMed  Google Scholar 

  36. Dudkowski C, Lee R, Wu R, et al. A phase 1 study to assess the effect of age, gender and race on the pharmacokinetics of single and multiple doses of Lu AA21004 in healthy subjects [abstract no. PII-48]. Clin Pharmacol Ther. 2012;91 Suppl 1:S69.

    Google Scholar 

  37. Chen G, Lee R, Hojer A-M, et al. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig. 2013;33(10):727–36.

    Article CAS PubMed Central PubMed  Google Scholar 

  38. Chen G, Lee R, Zhao Z, et al. A phase 1 study to assess the effect of LU AA21004 on the steady-state pharmacokinetics of lithium in healthy male subjects [abstract no. PI-84]. Clin Pharmacol Ther. 2012;91 Suppl 1:S39.

    Google Scholar 

  39. Lee RD, Wang Y, Zhao Z, et al. Effects of multiple doses of Lu AA21004 on the steady-state pharmacokinetics and pharmacodynamics of warfarin [abstract no. 1122787]. J Clin Pharmacol. 2011;51(9):1346.

    Google Scholar 

  40. Henigsberg N, Mahableshwarkar AR, Jacobsen P, et al. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry. 2012;73(7):953–9.

    Article CAS PubMed  Google Scholar 

  41. Baldwin DS, Loft H, Dragheim M. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol. 2012;22(7):482–91.

    Article CAS PubMed  Google Scholar 

  42. Mahableshwarkar AR, Jacobsen PL, Chen Y. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin. 2013;29(3):217–26.

    Article CAS PubMed  Google Scholar 

  43. Jain R, Mahableshwarkar AR, Jacobsen PL, et al. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol. 2013;16(2):313–21.

    Article CAS PubMed  Google Scholar 

  44. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012;27(4):215–23.

    Article PubMed  Google Scholar 

  45. Mahableshwarkar A, Jacobsen PL, Serenko M, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder [abstract no. NR9-02]. 166th annual meeting of the American Psychiatric Association; 18–22 May 2013; San Francisco.

  46. Jacobsen P, Mahableshwarkar AR, Serenko M, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder [abstract no. NR9-06]. 166th annual meeting of the American Psychiatric Association; 18–22 May 2013; San Francisco.

  47. Mahableshwarkar A, Jacobsen PL, Serenko M, et al. A duloxetine-referenced fixed dose study comparing efficacy and safety of 2 vortioxetine doses in the acute treatment of adult patients with MDD [abstract no. NR9-01]. 166th annual meeting of the American Psychiatric Association; 18–22 May 2013; San Francisco.

  48. Haggstrom L, Nielsen RZ, Danchenko N, et al. A randomized, double-blind, study of vortioxetine versus agomelatine in adults with major depressive disorder (MDD) with inadequate response to SSRI/SNRI treatment [abstract no. P.2.f.029]. Eur Neuropsychopharmacol. 2013;23 Suppl 2:S412.

    Article  Google Scholar 

  49. Boulenger JP, Loft H, Olsen CK. Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol. 2013. doi:10.1097/YIC.0000000000000018.

    PubMed  Google Scholar 

  50. Boulenger J-P, Loft H, Florea I. A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder. J Psychopharmacol (Oxf). 2012;26(11):1408–16.

    Article  Google Scholar 

  51. Baldwin DS, Hansen T, Florea I. Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder. Curr Med Res Opin. 2012;28(10):1717–24.

    Article CAS PubMed  Google Scholar 

  52. Alam MY, Jacobsen PL, Chen Y, et al. Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study. Int Clin Psychopharmacol. 2013. doi:10.1097/YIC.0000000000000010.

    Google Scholar 

  53. Filippov G, Christens PF. Vortioxetine (Lu AA21004) 15 and 20 mg/day: open-label long-term safety and tolerability in major depressive disorder [abstract no. P.2.b.011]. Eur Neuropsychopharmacol. 2013;23 Suppl 2:s325.

    Article  Google Scholar 

  54. Alvarez E, Perez V, Dragheim M, et al. A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol. 2012;15(5):589–600.

    Article CAS PubMed Central PubMed  Google Scholar 

  55. Florea I, Dragheim M, Loft H. The multimodal antidepressant Lu AA21004: open-label long-term safety and tolerability study in major depressive disorder [abstract no. P.2.c.010]. Eur Neuropsychopharmacol. 2012;22 Suppl 2:S255–6.

    Article  Google Scholar 

  56. Bidzan L, Mahableshwarkar AR, Jacobsen P, et al. Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial. Eur Neuropsychopharmacol. 2012;22(12):847–57.

    Article CAS PubMed  Google Scholar 

  57. Rothschild AJ, Mahableshwarkar AR, Jacobsen P, et al. Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States. Eur Neuropsychopharmacol. 2012;22(12):858–66.

    Article CAS PubMed  Google Scholar 

  58. Baldwin DS, Loft H, Florea I. Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder. Int Clin Psychopharmacol. 2012;27(4):197–207.

    Article PubMed  Google Scholar 

  59. Lundbeck AS. Lundbeck announces positive results for Brintellix (vortioxetine) in adult patients with major depression and inadequate response to SSRI or SNRI therapy [media release]; 2013.http://www.lundbeck.com.

Download references

Author information

Authors and Affiliations

  1. Adis R & D Insight, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand

    Andrew Gibb

  2. Adis, Auckland, New Zealand

    Emma D. Deeks

Authors
  1. Andrew Gibb

    You can also search for this author inPubMed Google Scholar

  2. Emma D. Deeks

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toAndrew Gibb.

Additional information

This profile has been extracted and modified from theAdis R&DInsight drug pipeline database.Adis R&D Insight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch.

Rights and permissions

About this article

Access this article

Subscribe and save

Springer+ Basic
¥17,985 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Japan)

Instant access to the full article PDF.

Advertisement

[8]ページ先頭
©2009-2025 Movatter.jp